The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy?

FASEB J. 2008 Oct;22(10):3432-42. doi: 10.1096/fj.08-109355. Epub 2008 Jun 17.

Abstract

Several studies indicate that the nuclear factor-kappa B (NF-kappaB) -activation cascade plays a crucial role not only in immune responses, inflammation, and apoptosis but also in the development and processing of pathological pain. Accordingly, a pharmacological intervention into this pathway may have antinociceptive effects and could provide novel treatment strategies for pain and inflammation. In this review we summarize the role of NF-kappaB in the nervous system, its impact on nociception, and several approaches that investigated the effects of various modulators of the classical I-kappaB-kinase-NF-kappaB signal transduction pathway in inflammatory nociception and neuropathic pain. The results indicate that NF-kappaB has an impact on nociceptive transmission and processing and that a number of substances that inhibit the NF-kappaB-activating cascade are capable of reducing the nociceptive response in different animal models. Therefore, a modulation of specific participants in the NF-kappaB signal transduction might exert a useful approach for the development of new painkillers.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Analgesics / pharmacology
  • Analgesics / therapeutic use*
  • Animals
  • Humans
  • I-kappa B Kinase / metabolism*
  • Mice
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / genetics
  • NF-kappa B / metabolism*
  • Nervous System / drug effects
  • Nervous System / metabolism
  • Pain / drug therapy*
  • Pain / genetics
  • Pain / metabolism

Substances

  • Analgesics
  • NF-kappa B
  • I-kappa B Kinase